Cargando…

Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma

OBJECTIVE: Hepatocellular carcinoma (HCC) is one of the most common and malignant tumors with an insidious onset, difficult early diagnosis, and limited therapy options, resulting in a poor prognosis. Cell division cycle associated 2 (CDCA2), also known as Repo-Man, plays an important role in regula...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zhenjun, Zhang, Yu, Shao, Shuai, Liu, Qi, Li, Yuhan, Du, Xiaoxiao, Zhang, Kun, Zhang, Mengxia, Yuan, Haixia, Yuan, Qiang, Liu, Tong, Gao, Yingtang, Wang, Yijun, Hong, Wei, Han, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517522/
https://www.ncbi.nlm.nih.gov/pubmed/34660326
http://dx.doi.org/10.3389/fonc.2021.755814
_version_ 1784584037547900928
author Yu, Zhenjun
Zhang, Yu
Shao, Shuai
Liu, Qi
Li, Yuhan
Du, Xiaoxiao
Zhang, Kun
Zhang, Mengxia
Yuan, Haixia
Yuan, Qiang
Liu, Tong
Gao, Yingtang
Wang, Yijun
Hong, Wei
Han, Tao
author_facet Yu, Zhenjun
Zhang, Yu
Shao, Shuai
Liu, Qi
Li, Yuhan
Du, Xiaoxiao
Zhang, Kun
Zhang, Mengxia
Yuan, Haixia
Yuan, Qiang
Liu, Tong
Gao, Yingtang
Wang, Yijun
Hong, Wei
Han, Tao
author_sort Yu, Zhenjun
collection PubMed
description OBJECTIVE: Hepatocellular carcinoma (HCC) is one of the most common and malignant tumors with an insidious onset, difficult early diagnosis, and limited therapy options, resulting in a poor prognosis. Cell division cycle associated 2 (CDCA2), also known as Repo-Man, plays an important role in regulating mitosis and DNA repair, but the involvement of CDCA2 in HCC remains unclear. METHODS: The differentially expressed genes that were significantly upregulated in multiple RNA sequencing datasets of HCC were screened. Receiver operating characteristic (ROC) curve analysis was performed to identify diagnostic markers for HCC. Least absolute shrinkage and selection operator Cox regression analysis was performed to screen the prognosis-related genes. The screening and analyses identified CDCA2 as the target gene in this study. The expression of CDCA2 was analyzed in public databases and clinical specimens, and CDCA2 involvement in HCC was explored by both bioinformatic analysis and in vitro experiments. RESULTS: The level of CDCA2 was enhanced in HCC compared with healthy livers. Overexpression of CDCA2 positively correlated with the pathological grade and TNM stage of the diseases. Furthermore, CDCA2 was found to be an independent prognostic predictor. An excellent prognostic model of HCC was successfully constructed with CDCA2 in combination with TNM stage. Bioinformatic analysis revealed that CDCA2 was closely associated with the cell cycle, apoptosis, and p53 signaling pathway. Silencing CDCA2 in Huh7 cells resulted in significant upregulation of p53 and the downstream PUMA and NOXA and a subsequently increased apoptosis. Inhibition of p53 signaling and apoptosis was found after overexpression of CDCA2 in L02 cells. Strikingly, the proliferation of cells was not affected by CDCA2. CONCLUSIONS: CDCA2 was a novel diagnostic marker for HCC, and overexpression of this gene reflected poor pathological grade, stage, and clinical prognosis. CDCA2 promoted the pathogenesis of HCC by suppressing the p53-PUMA/NOXA signaling and the subsequent apoptosis.
format Online
Article
Text
id pubmed-8517522
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85175222021-10-16 Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma Yu, Zhenjun Zhang, Yu Shao, Shuai Liu, Qi Li, Yuhan Du, Xiaoxiao Zhang, Kun Zhang, Mengxia Yuan, Haixia Yuan, Qiang Liu, Tong Gao, Yingtang Wang, Yijun Hong, Wei Han, Tao Front Oncol Oncology OBJECTIVE: Hepatocellular carcinoma (HCC) is one of the most common and malignant tumors with an insidious onset, difficult early diagnosis, and limited therapy options, resulting in a poor prognosis. Cell division cycle associated 2 (CDCA2), also known as Repo-Man, plays an important role in regulating mitosis and DNA repair, but the involvement of CDCA2 in HCC remains unclear. METHODS: The differentially expressed genes that were significantly upregulated in multiple RNA sequencing datasets of HCC were screened. Receiver operating characteristic (ROC) curve analysis was performed to identify diagnostic markers for HCC. Least absolute shrinkage and selection operator Cox regression analysis was performed to screen the prognosis-related genes. The screening and analyses identified CDCA2 as the target gene in this study. The expression of CDCA2 was analyzed in public databases and clinical specimens, and CDCA2 involvement in HCC was explored by both bioinformatic analysis and in vitro experiments. RESULTS: The level of CDCA2 was enhanced in HCC compared with healthy livers. Overexpression of CDCA2 positively correlated with the pathological grade and TNM stage of the diseases. Furthermore, CDCA2 was found to be an independent prognostic predictor. An excellent prognostic model of HCC was successfully constructed with CDCA2 in combination with TNM stage. Bioinformatic analysis revealed that CDCA2 was closely associated with the cell cycle, apoptosis, and p53 signaling pathway. Silencing CDCA2 in Huh7 cells resulted in significant upregulation of p53 and the downstream PUMA and NOXA and a subsequently increased apoptosis. Inhibition of p53 signaling and apoptosis was found after overexpression of CDCA2 in L02 cells. Strikingly, the proliferation of cells was not affected by CDCA2. CONCLUSIONS: CDCA2 was a novel diagnostic marker for HCC, and overexpression of this gene reflected poor pathological grade, stage, and clinical prognosis. CDCA2 promoted the pathogenesis of HCC by suppressing the p53-PUMA/NOXA signaling and the subsequent apoptosis. Frontiers Media S.A. 2021-10-01 /pmc/articles/PMC8517522/ /pubmed/34660326 http://dx.doi.org/10.3389/fonc.2021.755814 Text en Copyright © 2021 Yu, Zhang, Shao, Liu, Li, Du, Zhang, Zhang, Yuan, Yuan, Liu, Gao, Wang, Hong and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yu, Zhenjun
Zhang, Yu
Shao, Shuai
Liu, Qi
Li, Yuhan
Du, Xiaoxiao
Zhang, Kun
Zhang, Mengxia
Yuan, Haixia
Yuan, Qiang
Liu, Tong
Gao, Yingtang
Wang, Yijun
Hong, Wei
Han, Tao
Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma
title Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma
title_full Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma
title_fullStr Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma
title_full_unstemmed Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma
title_short Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma
title_sort identification of cdca2 as a diagnostic and prognostic marker for hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517522/
https://www.ncbi.nlm.nih.gov/pubmed/34660326
http://dx.doi.org/10.3389/fonc.2021.755814
work_keys_str_mv AT yuzhenjun identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT zhangyu identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT shaoshuai identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT liuqi identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT liyuhan identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT duxiaoxiao identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT zhangkun identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT zhangmengxia identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT yuanhaixia identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT yuanqiang identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT liutong identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT gaoyingtang identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT wangyijun identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT hongwei identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma
AT hantao identificationofcdca2asadiagnosticandprognosticmarkerforhepatocellularcarcinoma